|
Dec 11
|
Bristol Myers Squibb Presents New Data at ASH 2023 Demonstrating Clinical Benefit Across B-cell Malignancies with Breyanzi as a Second-Line Treatment in High-Risk Follicular Lymphoma and in Relapsed or Refractory Chronic Lymphocytic Leukemia
|
|
Dec 9
|
Bristol Myers Squibb Presents Primary Efficacy and Safety Analysis of the Phase 3 COMMANDS Trial of Reblozyl for Treatment of Anemia in Erythropoiesis Stimulating Agent-Naïve Patients with Lower-Risk Myelodysplastic Syndromes at ASH 2023
|
|
Dec 7
|
Bristol Myers Squibb Announces Phase 3 CheckMate -8HW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Compared to Chemotherapy in Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer Meets Primary...
|
|
Dec 7
|
Bristol Myers Squibb Announces Additional $3 Billion Share Repurchase Authorization
|
|
Dec 6
|
Bristol Myers Squibb Announces Dividend Increase
|
|
Dec 5
|
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy for the First-Line Treatment of Adult Patients with Unresectable or Metastatic...
|
|
Nov 28
|
FDA Looking Into All Approved CAR T Therapies on Risk of Cancer in White Blood Cells
|
|
Nov 28
|
Avidity Biosciences Announces Expansion of Cardiovascular Collaboration with Bristol Myers Squibb for up to Five Targets Utilizing Avidity's Proprietary AOC™ Platform Technology
|
|
Oct 3
|
The 10 pharma companies participating in Medicare price negotiations
|
|
Aug 25
|
AstraZeneca files lawsuit against U.S. over drug pricing
|
|
Aug 25
|
Retrospective Observational Study Assessing Real-World Clinical Impact of Switching or Continuing Eliquis® or Rivaroxaban Presented at the European Society of Cardiology (ESC) Congress 2023
|
|
Aug 24
|
AARP to join US government in two more lawsuits over Medicare drug pricing negotiations
|
|
Aug 23
|
Bristol Myers Squibb Shares Progress Toward Its Environmental, Social, and Governance Initiatives and Its Health Equity Commitments
|
|
Aug 22
|
Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma
|
|
Aug 21
|
Medicare drug price negotiations unlikely to be derailed by lawsuits: UBS
|
|
Aug 21
|
Bristol Myers Squibb to Showcase Data Across its Innovative Cardiovascular Portfolio at the European Society of Cardiology Congress 2023
|
|
Jul 21
|
Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma
|
|
Jul 20
|
J&J CFO: Medicare and Health Dept. are 'going after the wrong target' to reduce drug price inflation
|